Yuhan Joins Immuno-Oncology Wave Via Sorrento JV
This article was originally published in PharmAsia News
One of South Korea's leading pharma firms, Yuhan, is joining the global immuno-oncology wave by setting up a majority-owned joint venture with US-based Sorrento Therapeutics. The JV, Yuhan’s first in R&D, is set to develop and commercialize three of Sorrento's immune checkpoint antibodies.
You may also be interested in...
Yuhan and Luoxin's licensing agreement for a third generation EGFR inhibitor, the second such deal between South Korea and China, suggests robust demand for novel drugs for non-small cell lung cancer in Asia.
EyeGene R&D head talks to Scrip at CPhI Korea about the development of its COVID-19 vaccine candidate EG-COVID, potential challenges in clinical trials and positioning and the over-riding importance of validating a viable mRNA platform.
EuBiologics CEO Yeong Ok Baik sat down with Scrip at CPhI Korea to talk about why he wants to develop vaccines for global public health needs and what plans are in store for its late-stage recombinant protein candidate for COVID-19.